| Direct Competitor Comparison | |
|---|
| MRK | GSK | NVS | PFE | Industry |
|---|
| Market Cap: | 144.19B | 127.08B | 179.67B | 208.54B | 64.52B |
|---|
| Employees: | 83,000 | 99,488 | 129,000 | 89,400 | 99.49k |
|---|
| Qtrly Rev Growth (yoy): | -0.09 | -0.03 | 0.02 | -0.09 | 0.11 |
|---|
| Revenue (ttm):
| 46.21B | 42.21B | 57.80B | 57.60B | 27.01B |
|---|
| Gross Margin (ttm): | 0.65 | 0.71 | 0.68 | 0.81 | 0.61 |
|---|
| EBITDA (ttm): | 16.36B | 14.49B | 17.15B | 25.34B | 10.37B |
|---|
| Operating Margin (ttm):
| 0.21 | 0.28 | 0.22 | 0.32 | 0.16 |
|---|
| Net Income (ttm): | 6.02B | 6.78B | 9.66B | 10.52B | N/A |
|---|
| EPS (ttm): | 1.96 | 2.74 | 3.94 | 2.09 | 3.27 |
|---|
| P/E (ttm): | 24.36 | 19.18 | 18.56 | 14.07 | 14.20 |
|---|
| PEG (5 yr expected): | 4.51 | 4.12 | 2.61 | 4.82 | 0.96 |
|---|
| P/S (ttm): | 3.12 | 3.03 | 3.12 | 3.59 | 2.23 |
|---|
|
| GSK = GlaxoSmithKline plc | | NVS = Novartis AG | | PFE = Pfizer Inc. | | Industry = Drug Manufacturers - Major | |
| Biotechnology Companies Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Amgen Inc. | AMGN | 101.50 | 0.02 | 76.12B | 17.18 |
|---|
| Genentech, Inc. | "Private" |
|---|
| Biogen Idec Inc. | BIIB | 210.80 | 0.01 | 50.04B | 33.45 |
|---|
| Genzyme Corporation | "Private" |
|---|
| Merck Serono S.A. | "Private" |
|---|
| Gilead Sciences Inc. | GILD | 51.94 | 0.02 | 79.23B | 29.08 |
|---|
| MedImmune, L.L.C. | "Private" |
|---|
| Life Technologies Corporation | LIFE | 74.27 | 0.00 | 12.78B | 31.44 |
|---|
| Teva Pharmaceutical Industries Limited | TEVA | 39.64 | 0.01 | 33.77B | 19.79 |
|---|
| Sandoz International GmbH | "Private" |
|---|
|
| Generic Drugmakers Ranked by Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Actavis, Inc. | ACT | 125.67 | 0.01 | 16.05B | N/A |
|---|
| Ranbaxy Laboratories Limited | "Private" |
|---|
| Mylan, Inc. | MYL | 31.87 | 0.01 | 12.15B | 21.29 |
|---|
| Pfizer Inc. | PFE | 29.40 | 0.01 | 208.54B | 14.07 |
|---|
| Johnson & Johnson | JNJ | 86.36 | 0.01 | 242.58B | 23.45 |
|---|
| GlaxoSmithKline plc | GSK | 52.47 | -0.01 | 127.08B | 19.18 |
|---|
| Sanofi | SNY | 54.56 | -0.01 | 144.41B | 26.89 |
|---|
| Novartis AG | NVS | 73.12 | -0.00 | 179.67B | 18.56 |
|---|
| Roche Holding AG | RHHBY | 62.45 | 0.00 | 211.95B | 20.90 |
|---|
| AstraZeneca PLC | AZN | 50.98 | 0.00 | 63.72B | 11.28 |
|---|
|
| Drugmakers Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Abbott Laboratories | ABT | 37.51 | 0.02 | 58.47B | 11.43 |
|---|
| Bristol-Myers Squibb Company | BMY | 46.85 | 0.01 | 76.95B | 53.06 |
|---|
|
| News on Direct Competitors | |
|---|
- NVS
- Positive Data on Novartis' Jakavi Zacks Tue 4:55pm
- NVS
- Positive Data on Incyte's Jakafi Zacks Tue 4:00pm
- NVS
- Ariad's Iclusig in GIST Phase II Study Zacks Tue 3:30pm
- GSK
- 3 Views for Sarepta on Prosensa's IPO at Motley Fool Tue 2:56pm
- GSK
- RDInvesting Provides Investors with Free In-Depth Equity Reports on CSIQ, GSK, KSS and LMT Accesswire Tue 8:40am
- PFE
- Court appoints lead plaintiff in shareholder lawsuit against SAC Reuters Mon 11:56pm
- PFE
- Wall Street Fundamentals Releases New In-Depth Stock Reports on AXP, BIIB, PGE, TGT Accesswire Thu, Jun 13
- PFE
- Combining Therapies to Amplify the Effects of Statins Accesswire Wed, Jun 12
- PFE
- Regenerative Medicine Investors Eyeing Reformation of Pharmaceutical Affairs Law in Japan Accesswire Mon, Jun 10
- GSK
- GSK, AZN, KERX, and RPTP Early Briefing and Review Accesswire Fri, Jun 7
- PFE
- Analysis: SAC insider-trading probe could last years Reuters Thu, Jun 6
- GSK
- Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products Business Wire Mon, Jun 3
- NVS
- MDT, HLF, OREX, and NVS Early Briefing and Review Accesswire Mon, May 6
- GSK
- GSK, AZN, KERX, and RPTP Early Briefing and Review Accesswire Thu, May 2
- NVS
- Investing in Big Pharma Canadian Business Online Thu, Sep 13
All headlines for these symbols... Currency in USD. | |
|
0.05(0.10%) 4:00PM EDT|After Hours
:
47.83